Free Trial

Skye Bioscience Q3 2023 Earnings Report

Skye Bioscience logo
$2.98 -0.15 (-4.79%)
As of 02/21/2025 04:00 PM Eastern

Skye Bioscience EPS Results

Actual EPS
-$3.17
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Skye Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Skye Bioscience Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Skye Bioscience Earnings Headlines

Skye Bioscience to Present at TD Cowen Health Care Conference
Secret financial plot unfolding in Washington DC… [DEVELOPING]
What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. You see, I’ve recently uncovered a secret financial plot unfolding in Washington DC…
Leo Miller: Page 3
Craig-Hallum Reaffirms Their Buy Rating on Skye Bioscience (SKYE)
See More Skye Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Skye Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skye Bioscience and other key companies, straight to your email.

About Skye Bioscience

Skye Bioscience (NASDAQ:SKYE), a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

View Skye Bioscience Profile

More Earnings Resources from MarketBeat